A Phase 1 interventional study of CPO301 in Cancer and Cancer, Lung, sponsored by Conjupro Biotherapeutics, Inc.. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Conjupro Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,461 studies in Lung Neoplasms with a site in United States — 422 open to participants now, 643 under way, 52 of them phase 3. Lung Neoplasms · United States.
Among the 2,461 studies in Lung Neoplasms with a site in United States, this one is the 474th largest by planned enrollment of the 1,907 interventional ones that give a count, is one of 120 that started in 2023, is one of 448 in phase 1, reaches primary completion later than 278 of the 637 other live ones, and was the 2,092nd registered.
5,432 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.
Browse Lung Neoplasms studies →422 of the 2,461 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–77 · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–80 · Healthy volunteers
Roswell Park Cancer Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,461 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 660 · Phase 2 865 · Phase 3 179 · Phase 4 21
First in 1990; this study’s year is marked. 120 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 132 is above the median of 60 across 3,665 interventional studies indexed under Lung Neoplasms.
Median enrollment 48 across the 1,907 interventional studies, 123 across the 442 observational. Of the 1,674 that completed or were terminated, 582 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
619 of 2,461 have an industry lead sponsor. The 10 most frequent:
Conjupro Biotherapeutics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Conjupro Biotherapeutics, Inc. has 2 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
243 of the studies in Lung Neoplasms with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07499674Phase 3Vergent Bioscience, Inc.Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT04093167Phase 3Canadian Cancer Trials GroupStudy of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | 2026-12-31 |
| NCT03391869Phase 3M.D. Anderson Cancer CenterNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | 2027-03-31 |
Add all 243 to your calendar (.ics) → With an account.
Among the 2,461 studies in Lung Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.
The main questions it aims to answer are:
Participants will:
This Phase 1 study is a multicenter, dose-escalating, dose-expansion, single agent, 2-part study conducted in patients with advanced or metastatic solid tumors who progressed on ≥1 prior conventional systemic therapy or who were ineligible or intolerant to standard treatment or had no or refused standard treatment.
Dose escalation (Part A) - Dose escalation will be guided by a modified 3+3 design to determine the maximum tolerated dose (MTD) or recommended dose of CPO301 (also known as SYS6010). Determination of dose-limiting toxicity (DLT) will be based on toxicity observed during the DLT observation period (first 21 days [1 cycle]). Dose escalation decisions are made based on the occurrence of DLT. MTD will be determined based on the data of all enrolled participants. To better identify the MTD, one or more dose groups may also be added beyond the planned maximum dose group (if determined to be safe), or between the maximum escalation dose group and the next lower dose group for DLT assessment. Intermediate dose groups and/or adjustment to the dosing frequency may be made
Dose expansion (Part B) - Additional patients will be enrolled at the recommended dose determined in the dose escalation stage. An additional tumor cohort may be added based on data observed in Part A.
5,432 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.
This study's planned enrollment of 132 is above the median of 60 across 3,665 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Conjupro Biotherapeutics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Compared within Lung Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Major Inclusion Criteria:
Major Exclusion Criteria:
Prior therapy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive escalating doses of CPO301 of 0.6 mg/kg, 1.8mg/kg, 3.6 mg/kg, 4.8 mg/kg, 6.4 mg/kg and 8 mg/kg administered by IVI every 3 weeks (Q3W), with 21 days as a treatment cycle.
Drug: CPO301
Participants receive CPO301 at the recommended phase 2 dose (RP2D) determined in Part A, administered by IVI every 3 weeks (Q3W), with 21 days as a treatment cycle.
Drug: CPO301
Administered by intravenous injection
Also known as: SYS6010
To determine the dose to be used in Part B (RP2D)
To determine the recommended dose of CPO301 to be used as monotherapy in Part B (RP2D)
Time frame: through study completion, an average of 1 year
Safety and tolerability at RP2D of CPO301 as monotherapy
as measured by Incidence and severity of AEs per CTCAEv5.0
Time frame: through study completion, an average of 1 year
Pharmacokinetics (PK)
The pharmacokinetics (PK) profile of CPO301 will be assessed by measuring the blood concentration of the drug in the plasma at various timepoints and calculation of parameters, such as Peak Plasma Concentration (Cmax)
Time frame: through study completion, an average of 1 year
Expression of anti-drug antibody (ADA)
The expression of anti-drug antibodies (ADAs) following administration will be assessed by analysis of serum samples.
Time frame: through study completion, an average of 1 year
Efficacy assessment
To document any early indication of clinical efficacy
Time frame: through study completion, an average of 1 year
Parts A and B, Exploratory: Correlatives
To explore the correlation between EGFR status (different mutations, or amplification levels) and efficacy in patients with advanced solid tumors and biomarkers relevant to CPO301 efficacy
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for May 2027, 47 months after the start.
Of 129 industry-sponsored phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 47 months is above that.
Counting every sponsor, half of 293 studies reached it within 52 months; a quarter within 28 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-EGFR Antibody-drug Conjugate CPO301
Conjupro Biotherapeutics, Inc.